Reprint
Feature Paper in Antibiotics for 2019
Edited by
September 2020
282 pages
- ISBN978-3-03943-122-9 (Hardback)
- ISBN978-3-03943-123-6 (PDF)
This book is a reprint of the Special Issue Feature Paper in Antibiotics for 2019 that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
There has been much speculation about a possible antibiotic Armageddon; this would be the result of having untreatable post-operative infections, and similarly untreatable complications after chemotherapy. The now famous “O’Neill Report” (https://amr-review.org/) suggests that more people could die from resistant bacterial infections by 2050 than from cancer. We are still learning about all the subtle drivers of antibiotic resistance, and realizing that we need a single “whole of health” co-ordinated policy. We ingest what we sometimes feed to animals. There do not seem to be any new classes of antibiotics on our horizon. Perhaps something that has been around “forever” will come to our rescue—bacteriophages! Nevertheless, we have to do things differently, use antibiotics appropriately, for the correct indication, for the correct duration and with the correct dose, and with that, practice good antibiotic stewardship. Whilst by no means comprehensive, this book does cover some of the many topics of antibiotic stewardship. It also addresses some of the older antibiotics, some new combinations, and even some new agents. Last, and by no means least, there are two excellent articles on bacteriophages.
Format
- Hardback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
Antimicrobial resistance; antibiotics; antimicrobial stewardship; inappropriate prescribing; days of therapy; Start Smart then Focus; piperine; piperlongumine; antibacterial; antifungal; synergy; non-target feed; florfenicol; thiamfenicol; chloramfenicol; HPLC–MS/MS; validation; swine; antibiotics; out-of-hours care; primary care; quality of care; quality indicators; practitioners cooperative; antibiotic stewardship; antibiotics; fluoroquinolones; guidelines; urinary tract infections; quality improvement; general practitioners; primary care; antibiotics; guideline; antimicrobial stewardship; health inequalities; health equity assessment tool; public health; Enterobacteriaceae; carbapenem-resistant; CRE; antibiotic resistance; antimicrobials; bacteriophages; biofilms; novel antimicrobials; Antibiotics; resistance; broad-spectrum agents; hospital epidemiology; antibiotic utilization; infection control; infection prevention; Pseudomonas aeruginosa; Acinetobacter baumannii; extended-spectrum beta-lactamases; carbapenem-resistant Enterobacteriaceae; methicillin-resistant Staphylococcus aureus; bacteriophages; clinical trials; antibiotic resistance; infectious disease; phage therapy; silver complexes; camphorimine; anti-Candida activity; antifungals; antibacterials; efflux inhibitors; efflux pumps; erm(41); mutations; mycobacteria; verapamil; actinomycetes; bioactivity; antimicrobials; polyketides; polyketide synthases; biosynthesis; antimicrobial resistance; economic evaluation; cost-utility analysis; cost-effectiveness analysis; antibiotics; Antimicrobial resistance; policy analysis; One Health; public health; Singapore; antimicrobial stewardship; antibiotic prescribing; primary care; implementation; behavior change; stakeholder consultation; n/a